Transforming Adiponectin-EVs into Next-Gen Therapeutics

Our Mission

At ADEVBio, we’re pioneering a new approach to tackling chronic diseases like diabetes and heart disease. These conditions are linked to declining levels of adiponectin, a key hormone for metabolic and cardiovascular health. While some existing therapies and lifestyle interventions can influence adiponectin, none are designed to directly and precisely restore its protective effects. By harnessing extracellular vesicles, we aim to unlock a novel therapeutic pathway that supports healthier aging, advances cardiometabolic care, and extends healthspan.

Harnessing the body’s natural messengers to fight chronic disease.

ADEVBio’s platform combines the therapeutic potential of adiponectin, a hormone essential for metabolic and cardiovascular health, with the natural delivery power of extracellular vesicles (EVs). EVs act as the body’s communication system, tiny messengers that transfer proteins, lipids, and RNA between cells.

By engineering EVs to carry high levels of adiponectin, we create a novel, targeted therapy capable of restoring metabolic balance, reducing inflammation, and improving insulin sensitivity. Unlike traditional therapies, our approach leverages the body’s own biology for precise delivery, greater potency, and long-term impact.

This innovation opens new possibilities for treating chronic diseases such as type 2 diabetes, cardiovascular disease, and metabolic syndrome, while also advancing healthier aging and longevity.

News

ADEVBio accepted into Lab2Market Validate Program 2025

Sept 2025 - We’re excited to announce that ADEVBio has been accepted into the prestigious Lab2Market Validate Program, a Canadian accelerator designed to help researchers explore the commercial potential of their innovations. This milestone provides us with the resources, mentorship, and network to evaluate the market impact of our adiponectin-EV therapeutic platform.

Heading our business development efforts is Keera McNalty (Business Strategist, Lab2Market), who is leading the translation of our science into a strong commercialization pathway. This program marks a critical step forward in bringing our next-generation therapies closer to patients who need them most.

ADEVBio Showcased at OBIO Entrepreneurship Bootcamp Pitch Competition

Nov 2025 — ADEVBio was selected to participate in the Ontario Bioscience Innovation Organization (OBIO) Entrepreneurship Bootcamp, a 3-day intensive program bringing together emerging life science innovators from across Canada.

As part of the program, our Business Strategist Keera McNalty represented ADEVBio in the final Pitch Competition, presenting our adiponectin-EV platform to a panel of industry judges from Genesys Capital, Ontario Centre of Innovation, FACIT, and TIAP. The competition featured startups advancing solutions in medical devices, diagnostics, therapeutics, and biomanufacturing.

The event provided valuable feedback from investors and commercialization leaders, reinforcing the growing interest in next-generation biologics targeting cardiovascular inflammation and repair.

ADEVBio extends our thanks to OBIO, BioHubNet, and the program mentors for supporting the next wave of Canadian biotech founders.